BZL Biologics, LLC

Industry

  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
See more in Biomedtracker

Latest on BZL Biologics, LLC

Scrip

Novartis Eyes Broader Market As Pluvicto Hits Mark In Pivotal Second-Line mCRPC Trial

 
• By Ayisha Sharma

Novartis AG ’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has met the primary endpoint in a pivotal second-line prostate cancer trial, sparking plans for a US filing that could significantly boo

Scrip

ATLAB Pharma and BZL Biologics collaborate on radiopharmaceutical for prostate cancer

 
• By Pial Ganguli

France's ATLAB Pharma and US-based BZL Biologics have entered into a sublicence agreement to develop a radiopharmaceutical, 177Lu-J591, for cancer treatment. The deal includes exclusive rights to manu